Skip to search formSkip to main contentSkip to account menu

MK 0677

Known as: MK 677, MK-0677, MK-677 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ibutamoren mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults
Context The age-related decline of growth hormone secretion may play a role in sarcopenia and frailty. Content In this randomized… 
Highly Cited
2005
Highly Cited
2005
Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… 
Highly Cited
2004
Highly Cited
2004
The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture
Objectives: To evaluate the effects of MK‐0677, an orally active growth hormone (GH) secretagogue, on functional recovery from… 
Highly Cited
1999
Highly Cited
1999
A New Orphan Receptor Involved in Pulsatile Growth Hormone Release
Highly Cited
1998
Highly Cited
1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… 
Highly Cited
1998
Highly Cited
1998
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic… 
1998
1998
Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males
The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK‐677 on markers of bone metabolism was… 
Highly Cited
1998
Highly Cited
1998
Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues.
Highly Cited
1996
Highly Cited
1996
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Aging is associated with declining activity of the GH axis, possibly contributing to adverse body composition changes and… 
Highly Cited
1996
Highly Cited
1996
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young…
To assess the effects of prolonged administration of a novel analog of GH-releasing peptide (MK-677), nine healthy young men… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)